JBIO — Jade Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1798749 ·
Last close
$21.71
Market Cap
$1.07B
52W High
$28.00
52W Low
$12.91
ADV30
599,384
Next earnings
2026-05-14
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -43,445,000 | -40,368,000 | 319,433,000 | 55,085,000 | 22,971,000 |
| Dec 2025 | 0 | — | -34,979,000 | -31,932,000 | 349,781,000 | 88,438,000 | 17,263,000 |
| Sep 2025 | 0 | — | -27,401,000 | -25,175,000 | 202,450,000 | 50,106,000 | 23,104,000 |
| Jun 2025 | 0 | — | -27,778,000 | -32,134,000 | 223,968,000 | 220,942,000 | 22,412,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-78,387,000
Investing CF
$-246,870,000
Financing CF
$262,160,000
CapEx
$-60,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.03
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-174,389,000
Inventory
—
Receivables
$0
ST Investments
$247,720,000
EBIT TTM
$-110,141,000
Pretax Income TTM
$-119,295,000
Interest Exp TTM
—
Analysts
7
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -113,542,000 | -127,410,000 | 349,781,000 | 17,263,000 | — | -94,689,000 |
| Dec 2024 | — | — | — | 72,799,000 | 119,598,000 | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-27,430,000
OpCashFlow TTM
$0
Assets (Latest)
$127,418,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IVA | Inventiva S.A. | $1.08B | $5.16 | — |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.08B | $12.83 | — |
| XERS | Xeris Biopharma Holdings, Inc. | $1.08B | $6.26 | — |
| SVRA | Savara Inc | $1.05B | $5.14 | — |
| MNKD | MANNKIND CORP | $1.09B | $3.53 | — |
News headlines (Yahoo Finance, 1h cache)
Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody
2026-05-26 20:05 · Yahoo
Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy
2026-05-26 11:00 · Yahoo
Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-07 20:05 · Yahoo
Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-04-23 11:00 · Yahoo
Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer
2026-04-22 11:00 · Yahoo
Companies Like Jade Biosciences (NASDAQ:JBIO) Are In A Position To Invest In Growth
2026-03-28 12:14 · Yahoo
Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
2026-03-06 12:00 · Yahoo
Jade Biosciences Touts “Best-in-Class” Autoimmune Antibodies, JADE101 Phase 1 Readout Nears
2026-02-28 16:41 · Yahoo
Jade Biosciences to Participate in Upcoming Conferences
2026-02-11 12:00 · Yahoo
H.C. Wainwright Initiates Jade Biosciences (JBIO) at Buy With $25 PT as JADE101 Eyes $926M Peak Revenue
2026-01-19 13:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.